mortality/aging
• in paclitaxel-treated mice
|
immune system
• in paclitaxel-treated mice, the cortex of thymus is decreased in size due to increased lymphocyte apoptosis and/or depopulation compared to in wild-type mice
|
• in female mice treated with paclitaxel
|
• paclitaxel-treated mice exhibit decreased erythroid and myeloid cell proliferation, which are replaced with histocytes and stromal cells, compared to in similarly treated wild-type mice
|
small spleen
(
J:172648
)
• in paclitaxel-treated mice
|
• in paclitaxel-treated mice
|
• in paclitaxel-treated mice
|
• in paclitaxel-treated mice
|
growth/size/body
• in female mice treated with paclitaxel
|
homeostasis/metabolism
• paclitaxel-treated mice exhibit increased mortality, decreased body weight, decreased white blood cells, and hypoplasia of the bone marrow, spleen, and thymus compared with wild-type mice
|
hematopoietic system
• in paclitaxel-treated mice, the cortex of thymus is decreased in size due to increased lymphocyte apoptosis and/or depopulation compared to in wild-type mice
|
• in paclitaxel-treated mice
|
• in female mice treated with paclitaxel
|
• paclitaxel-treated mice exhibit decreased erythroid and myeloid cell proliferation, which are replaced with histocytes and stromal cells, compared to in similarly treated wild-type mice
|
small spleen
(
J:172648
)
• in paclitaxel-treated mice
|
• in paclitaxel-treated mice
|
• in paclitaxel-treated mice
|
• in paclitaxel-treated mice
|
endocrine/exocrine glands
• in paclitaxel-treated mice, the cortex of thymus is decreased in size due to increased lymphocyte apoptosis and/or depopulation compared to in wild-type mice
|